On Aug. 4, 2020, the NIH announced that patients admitted with COVID-19 at select hospitals may now volunteer to enroll in a clinical trial to test the safety and efficacy of a potential new treatment for the disease. The Phase 3 randomized, controlled trial is known as ACTIV-3, and as a ﾓmaster protocol,ﾔ it is designed to expand to test multiple different kinds of monoclonal antibody treatments.